Ranbaxy's Patent Litigations in the United States


IBS CDC IBS CDC IBS CDC IBS CDC RSS Feed
  
Case Studies | Case Study in Business, Management, Operations, Strategies, Business Case Study

ICMR HOME | Case Studies Collection

To download Ranbaxy's Patent Litigations in the United States case study (Case Code: ECON015) click on the button below, and select the case from the list of available cases:



» Economics Case Studies
» Case Studies Collection
» ICMR Home
» Short Cases Studies
» View Detailed Pricing Info
» How To Order This Case
» Business Case Studies


Please note:

This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.

Case Details:

Price:
Case Code : ECON015 For delivery in electronic format: Rs. 300;
For delivery through courier (within India): Rs. 300 + Rs. 25 for Shipping & Handling Charges

Themes

Corporate Social Responsibility

Themes

-
Case Length : 14 Pages
Period : 1993-2005
Pub Date : 2006
Teaching Note : Not Available
Organization : Ranbaxy Laboratories Limited
Industryy : Pharmaceutical
Countries : USA

Abstract:

The case focuses on Ranbaxy Laboratories Limited's patent litigations in the US. It elaborates on the factors that led to the company's global expansion, focusing specifically on the US market. The case discuses in detail Ranbaxy's approach to the US market and also discusses its initial successes. It also looks at the US pharmaceutical industry and the patent system in the US in detail. The Hatch-Waxman Act of 1984 and its significant impact on the generics pharma industry in the US are also explained. The case discusses the problems faced by the generics players in the US in the extremely competitive generics market and the effect of increasing patent litigation costs involved in challenging patent holders.

It ends with a note on Ranbaxy's challenges in meeting its target of $ 2 billion for the year 2007..

Issues:

» Growth strategy of a pharmaceutical company in the international market

» Benefits and downside of adopting of an inorganic growth strategy in an international market

» Nature and scope of the US pharmaceutical industry

» Legal and regulatory environment in the US

» How patent litigations can be the strategy of choice of generics players for revenue growth

» Impact of patent litigations on generics players as well as on patent holding companies

Contents:

  Page No.
Introduction 1
Background 2
The US Pharmaceutical Industry 3
Product Launches and Patent Litigations 5
Outlook 9
Exhibits 10

Keywords:

Ranbaxy Laboratories Limited, Pfizer, Lipitor, Teva Pharmaceuticals USA Inc., Glaxo Wellcome, Patent Litigations, Drug Price Control Order, Indian Patent Act of 1970, Ranbaxy Pharmaceuticals Inc., Food and Drug Administration (FDA), Generics, Patent and Trademark Office, Pharmaceutical Industry, Hatch-Waxman Act, Abbreviated New Drug Application, Paragraph IV (Para IV) certification, Eli Lilly, Cefaclor, Patent, Dr. Reddy's Laboratories

Ranbaxy's Patent Litigations in the United States - Next Page>>

 

Case Studies Links:- Case Studies, Short Case Studies, Simplified Case Studies.

Other Case Studies:- Multimedia Case Studies, Cases in Other Languages.

Business Reports Link:- Business Reports.

Books:- Textbooks, Work Books, Case Study Volumes.